INTRODUCTION
The prophylaxis of the hepatitis B infection by vaccination has been a major breakthrough in the control of this disease.
The use of vaccine is recommended in nemo dialysis units because of the high risk of dissemination of hepatitis B virus (HBV) due to the high frequency of chronic carriers among patients with renal failure (13) .
Several studies have demonstrated the efficacy of different plasma derived vaccines (Hevac B, Pasteur; Heptavax, MSD) in the prevention of hepatitis B in hemodialysis centers 6 7 and among high risk groups such as children living in endemic areas 17 and male homossexuais 18 .
In 1981, BRUMMELHUIS et al. 2 described a simplified method of preparation of heat-inactivated hepatitis B vaccine (CLB, Netherlands).
The efficacy and immunogenicity of this vaccine were demonstrated in healthy volunteers at low risk 15 and in some high risk groups 5 8 . This paper describes the evaluation of the immune response in hemodialysis patients and occupational risk personnel against CLB-3ftg vaccine.
MATERIALS AND METHODS

Vaccine: The CLB vaccine contains 22nm
particles of HBsAg of two different subtypes, ad (1) Departamento de Virologia. Fundação Oswaldo Cruz, Rio de Janeiro, Brazil
(2) CDR -Clínica de Doenças Renais, Rio de Janeiro.
(3) Bio-Manguinhos, Fundação Oswaldo Cruz, Rio de Janeiro, Brazil. and ay, purified by separation methods used for isolation of plasma components. The vaccine is heat inactivated, absorbed to aluminium phos phate and the final suspension contains 3#*g of HBsAg per dose. This vaccine was developed by the Central Laboratory of the Netherlands Red Cross Blood Transfusion Service (CLB), and was kindly provided to be evaluated in our he modialysis patients and occupational risk perso nnel. The vaccine was kept at 4°C in our labora tory until issued for inoculation.
Participants: The vaccine was tested in a total of 59 patients (38 males) at 5 hemodialysis centers. The mean age was 41 ±13 years and 38% had been submitted to hemodialysis for mo re than one year. Twenty occupational risk per sonnel (8 males) with a mean age of 28 ±8 were also vaccinated.
All participants were volunteers and only those who were negative for any HBV marker were selected for vaccination. After the begi nning of vaccination, blood specimens were ob tained from all subjects at monthly intervals du ring a period of one year to be tested for HBsAg and anti-HBs. (Table I ).
In the occupational risk personnel, all high and medium responders remained positive after the one year follow-up and only two who had developed low titers became negative during the period of study (Table I) . year. This is also lower than in other studies as Indeed, the fourth dose given to patients not only increased the seroconversion rate but its more noticeable effect was in the increase of antibody levels (Fig. 3 ).
It has been reported in some efficacy trials that only those persons who respond well, with at least one serum sample presenting more than 10 SRU, are protected from HBV infection 10 14 .
Considering this criterion, in our study only -27 fig, Pasteur-10  §ig, MSD-40 fig) have been employed with a significant improvement in protection level 11 12 . Better results might be obtained with the use of these more immunogenic vaccines and we suggest their evaluation in our country. 
RESUMO
